ANCO’s ASCO24 Highlights will summarize the major research and treatment advancements presented at this year’s ASCO24 Meeting. The program will focus on breast, gastrointestinal, genitourinary, gynecologic, hematologic malignancies, lung cancers, and sarcoma, as well as a plenary session. The faculty will place these developments in context as to their immediate clinical utility.

Location

For those attendees who are interested in attending in person, the program will be hosted at the Claremont Hotel & Spa, A Fairmont Hotel, 41 Tunnel Rd, Berkeley, CA 94705.

Registration is Complimentary for Physicians and the Cancer Care Community.  Registration will open in late Spring.

Industry Registration

At ANCO we strive to foster meaningful connections and facilitate valuable interactions among participants at our events. To ensure a fair distribution of attendance and provide an opportunity for various stakeholders to participate and engage with the cancer care community at large, industry registration for the event is intentionally limited to a maximum of three representatives per company, from companies who are not exhibiting at the event, with a maximum of 20 companies.

Corporate Member Supporters & Exhibitors

Corporate Member support for ANCO’s ASCO24 Highlights is in part from ANCO’s Sustaining Plus Level Corporate Members: AbbVie, Amgen, AstraZeneca, BeiGene USA, Inc., Bristol-Myers Squibb Oncology, Genmab, Gilead Sciences, Inc., GSK Oncology, Incyte Corporation, Jazz Pharmaceuticals, Inc., Johnson & Johnson, Kite, A Gilead Company, Merck & Co., Inc., Mirati Therapeutics, Pharmacyclics LLC, an AbbVie Company, Regeneron, Stemline, A Menarini Group Company, and Takeda Oncology. And Sustaining Level Corporate Members: Grail, Lilly Oncology, MorphoSys, Novartis Pharmaceuticals, Pfizer Oncology, Pharma Essentia USA Corporation, Seagen, and Taiho Oncology Inc.

Exhibitor support for ANCO’s ASCO24 Highlights is in part from Major Supporters: Daiichi Sankyo, Inc. and Sumitomo Pharma America, Inc. And Supporters: Exact Sciences, Exelixis, Inc., Karyopharm Therapeutics, Inc., and Puma Biotechnology, Inc.

ANCO’s ASCO24 Highlights Exhibit Hall is sold out.